Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SACT-1 (rilpivirine hydrochloride) is an orally administered repurposed small molecule drug for the treatment of neuroblastoma. SACT-1 enhance tumor cell death and suppress MYCN expression.
Product Name : SACT-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2023
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALS-4
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALS-4 is a small molecule drug based on an anti-virulence approach targeting staphylococcus aureus including MRSA. It targets antimicrobial resistant properties of the bacteria and is believed to render the bacteria highly susceptible to the host’s imm...
Product Name : ALS-4
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2023
Lead Product(s) : ALS-4
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dioscorea Polystachya
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China
Details : NativusWell® contains a novel, non-hormonal bioactive ingredient DOI, having anti-ageing and antioxidant effect is designed to support the overall health of women undergoing perimenopause, menopause and postmenopause.
Product Name : NativusWell
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2023
Lead Product(s) : Dioscorea Polystachya
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Aenco Technologies Limited
Deal Size : $3.0 million
Deal Type : Private Placement
Aptorum Group Announces Completion of $3 Million Convertible Note due 2023
Details : SACT-1 (rilpivirine) is an orally administered repurposed small molecule drug to target neuroblastoma. SACT-1’s mechanism has been investigated to enhance tumor cell death and suppress MYCN expression.
Product Name : SACT-1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 16, 2022
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Aenco Technologies Limited
Deal Size : $3.0 million
Deal Type : Private Placement
Lead Product(s) : Dioscorea Polystachya
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong
Details : NativusWell (dioscorea polystachya) contains a novel, non-hormonal bioactive ingredient DOI, designed to support health of women undergoing perimenopause, menopause and postmenopause.
Product Name : NativusWell
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2022
Lead Product(s) : Dioscorea Polystachya
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SACT-1 is an orally administered repurposed small molecule drug to target neuroblastoma. SACT-1’s mechanism has been investigated in our preclinical studies to enhance tumor cell death and suppress MYCN expression.
Product Name : SACT-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2022
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : USFDA has granted Orphan Drug Designation to SACT-1, an orally administered repurposed small molecule drug to target neuroblastoma on the basis of results that demonstrated enhanced tumor cell death and suppress MYCN expression in the preclinical studies...
Product Name : SACT-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2022
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALS-4
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4
Details : The primary objective of the trial is to evaluate the safety and tolerability of SAD and MAD of ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA.
Product Name : ALS-4
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2021
Lead Product(s) : ALS-4
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptorum Group Announces Significant Progress of SACT-1
Details : Subject to completion of current validation studies, Aptorum Group plans to leverage the 505(b)(2) pathway and submit an IND submission with the FDA for SACT-1 in H2 2020.
Product Name : SACT-1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2020
Lead Product(s) : Rilpivirine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALS-4
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptorum Group Announces Further Positive Data For Its ALS-4
Details : Subject to completion of the current studies, Aptorum Group targets to submit IND for ALS-4 in second half of 2020 and commence a phase 1 trial in North America.
Product Name : ALS-4
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2020
Lead Product(s) : ALS-4
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable